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Abstract
Time and timeliness are key issues in appraising and ensuring the clinical relevance of systematic
reviews. Time considerations entering the systematic review process include the history of the clinical
problem, disease, or treatment that is the target of the review, and the history of the research conducted
to address it. These considerations guide: (i) formulation of the research problems and questions; (ii)
setting of parameters for the search and retrieval of studies; (iii) determination of inclusion and
exclusion criteria; (iv) appraisal of the clinical relevance of findings; (v) selection of the findings
that will be synthesized; and (vi) interpretation of the results of that synthesis.
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Introduction
Systematic reviews are on the crest of a wave of popularity in the health care disciplines as the
pressure for evidence-based practice grows more intense. Systematic reviews of research,
especially syntheses of research findings, are advanced as a way to make sense of the hundreds
of results of the many studies conducted in common domains of research. Researchers and
clinicians increasingly rely on systematic reviews to sum up the state of knowledge in a field,
obtain answers to research and clinical questions that cannot be answered in individual studies,
resolve apparently conflicting results, confirm or provide a basis for altering existing practice,
and to direct future research agendas. This growing reliance on systematic reviews is evident,
not only in the growing number and variety of published systematic reviews, but also in the
burgeoning instructional and advice literature on systematic review, including the regularly
updated Cochrane Handbook for Systematic Reviews (Higgins and Green 2005), publication
of systematic review methods papers, including systematic reviews of systematic reviews
(Sander & Kitcher 2006), in virtually all of the major Western medicine, nursing and other
health-related journals, and in national funding of studies to develop systematic review
methods (Sandelowski et al. 2005; Popay 2006).
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One aspect of the systematic review process that has a major impact on the clinical relevance
of reviews, but that has yet to be adequately addressed, is the role of time. Reports of systematic
reviews typically include the dates of retrieval and publication of the reports selected for
review. What is typically not described, however, is what this information might mean for the
formulation of the research purpose for a systematic review, the selection of reports for the
review, the selection of the findings from those reports to synthesize, the interpretation of
review results, or for the overall relevance of the review for current practice. We address these
issues in this paper.
Methods
This paper is based on work completed in our ongoing study to develop methods to synthesize
qualitative and quantitative research findings in common domains of health-related research.
We chose to begin the work of this project with empirical studies of antiretroviral adherence
in HIV-positive women of any race, class, or nationality living in the United States. These
limitations were set largely to ensure a sample that was methodologically diverse enough to
permit, but not so topically or clinically diverse as to preclude, the methodological
experimentation at the heart of the project. In addition, we limited retrieval of reports to those
published after 1997 in the hopes of capturing studies conducted after highly active
antiretroviral therapy (HAART) became widely available. Indeed, it was after this date that
researchers became more interested in antiretroviral medication adherence in HIV-positive
patients. Especially compelling was the emerging problem of class resistance to protease
inhibitors, and the requirement –more urgent for HIV-positive patients than for patients
prescribed medications for other conditions – to achieve >95% adherence for full therapeutic
effectiveness and to avoid drug resistance (Paterson et al. 2000).
Our study thus far includes 42 reports (35 journal articles, six unpublished theses or
dissertations and one technical report), retrieved between June 2005 and January 2006. Of these
42 reports, 25 contained data ascertaining the relationship between aspects of the medication
regimen (independent variable) and adherence (dependent variable). Yet as we reviewed these
studies and began to notice the time-sensitive, or dated, nature of many of the findings
concerning medication regimen, we became increasingly concerned that several of the regimen
aspects studied (e.g. type and size of pills, number of pills per dose, number of doses per day,
diet restrictions surrounding pills) were no longer as relevant today as they once were. For
example, it is now commonplace for HIV-positive persons to take two pills once a day (and a
one-pill-once-a-day regimen will soon be available). Yet only a few years ago, patients had to
use large tool carts on wheels to store all of their medications. Although we had selected 1997
as the beginning publication date for the reports to be included in our study, several of the
studies were conducted before the advent of HAART, while others were conducted in the early
years of HAART when common reasons for non-adherence included pill burden and meal
restrictions. For example, as shown in Column 1 in Table 1, the data for the results featured
were collected as far back as 1993 in at least five reports. These concerns led us to focus on
time and timeliness as key issues in appraising and ensuring the clinical relevance of systematic
reviews.
Results
Time considerations entering the systematic review process include (i) the history of the clinical
problem, disease or treatment that is the target of the review, and (ii) the history of the research
conducted to address that target.
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History of disease and treatment
Foundational to all time considerations is the history of the clinical problem, disease or
treatment that is the focus of the systematic review. Understanding the historical context of the
target of the review allows reviewers to place study findings into their appropriate interpretive
context. A case in point is the field of HIV; few areas of health care have changed as rapidly
as the view and treatment of those infected with HIV. In one decade, advances in therapy have
transformed HIV/AIDS from a fatal to a chronic disease: from a disease viewed as one that
largely gay men died from to a chronic condition anyone could contract and that could not only
be lived with, but also lived with well.
Moreover, the treatment guidelines have changed dramatically over the last decade, with drugs
and drug regimens promoted and falling out of favour. For example, initially only zidovudine
was used to treat HIV infection. Introduced in March 1987, it was administered every 3 hours,
around the clock. With the advent of more drugs, the clinical problem became which drugs to
select and how to combine the two or more drugs selected for optimal treatment. Guidelines
issued in 1990 recommended routine prescription of zidovudine in all cases where the T helper
cells destroyed by HIV (CD4) count fell below 500. Revised guidelines indicated that drugs
might or might not be prescribed for patients with low CD4 counts but no symptoms (Macilwain
1993). After 1997, guidelines became more precise. Only in 2003 were guidelines fine-tuned
to recommend specific drugs and drug combinations.
In addition to rapid changes in the regimens themselves that served as backdrop to studies
addressing regimens as independent variables were changes in the philosophy of when to treat
HIV infection. The decision of when to treat was initially left largely to the discretion of the
clinician. Clinicians were then advised to wait to prescribe medications because so few of them
were available and drug resistance was emerging as a serious complication. A brief period
existed of ‘hit hard, hit early’ (Ho 1995), in which drugs were prescribed to any seropositive
patient who agreed to take the medication, because of the assumption that if the virus was
attacked early, it would not establish itself in the patient. Yet medication side-effects and
complex dosing requirements made this unworkable for many people. The current era is one
of caution, whereby treatment is offered only to patients whose CD4 count is between 200 and
350 and whose viral load is >100 000 (Department of Health and Human Services 2005).
Accordingly, changing philosophies about treatment likely explain the ambivalence or lack of
knowledge female participants in the reviewed studies often perceived in their providers and
the wide differences in the actual regimens studied. The era of treatment uncertainty was likely
a contributing factor to these findings in studies of that era aimed at ascertaining the link
between medication regimen and adherence.
As shown in Table 1, of the 42 reports of studies reviewed in our project, four indicated that
data were collected pre-HAART (1996 or earlier); 27 indicated that data were collected post-
HAART (1997–2005); and five indicated that data were collected in the period spanning pre-
and post-HAART. (In six reports, the dates of data collection remain unknown as we were
unable to obtain this information from primary authors of these reports.) Favouring adherence
were regimens featured in the more current studies reviewed, including simpler regimens
(Abel & Painter 2003), simpler timing of the medication regimen (Gant & Welch 2004), once-
or twice-a-day dosing (Powell-Cope et al. 2003), and having fewer pills to take (Stone et al.
2001). These factors continue to be relevant as they characterize the most commonly used
current regimens to treat anti-retroviral (ARV)-naïve patients. For example, the older protease
inhibitor-based preferred regimen involved taking eight pills twice a day with food to reduce
gastrointestinal side-effects. In contrast, the newer non-nucleoside reverse transcriptase
inhibitors (NNRTI)-based preferred regimen consists of two pills once a day, which should be
taken on an empty stomach at bedtime (Department of Health and Human Services 2005).
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Although the most prominent side-effects in the NNRTI-based regimen are the neurological
effects associated with efavirenz, these effects usually subside after several weeks.
Knowledge of these regimens, and how they have changed dramatically in such a short period
of time, served as a backdrop for reviewing the findings; they are listed in Table 1. Of the 42
reports, 17 indicated that medication side-effects were a key factor in non-adherence (Siegel
& Gorey 1997;Roberts & Mann 2000;Fourney 1999;Schuman et al. 2001;Wilson et al.
2001;Erlen et al. 2002;Garcia-Teague 2002;Howard et al. 2002;Richter et al. 2002;Abel &
Painter 2003;Douglass et al. 2003;Jones et al. 2003;Mellins et al. 2003;Powell-Cope et al.
2003;Gant & Welch 2004;Wood et al. 2004;Phillips et al. 2005). Also negatively affecting
adherence were complexity of drug regimens (Turner et al. 2000;Stone et al. 2001;Garcia-
Teague 2002;Abel & Painter 2003;Gant & Welch 2004) and, specifically, having too many
pills to take (Stone et al. 2001;Durante et al. 2003;Jones et al. 2003;Mellins et al. 2003;Gant
& Welch 2004;Wood et al. 2004;Phillips et al. 2005), having difficulty fitting the treatment
schedule into one’s daily schedule (Roberts & Mann 2000;Fourney 1999;Wilson et al.
2001;Garcia-Teague 2002;Howard et al. 2002;Phillips et al. 2005), and dietary requirements
or restrictions (Roberts & Mann 2000;Stone et al. 2001;Garcia-Teague 2002;Powell-Cope et
al. 2003;Phillips et al. 2005). The characteristics of the pills themselves (e.g. taste, size) were
also found to be factors hindering adherence (Roberts & Mann 2000;Garcia-Teague
2002;Powell-Cope et al. 2003). Several reports featured fears regarding drug toxicity or lack
of efficacy, either for the woman herself (Siegel & Gorey 1997;Fourney 1999;Schuman et
al. 2001;Siegel et al. 2001;Wilson et al. 2001;Erlen et al. 2002;Richter et al. 2002;Durante et
al. 2003;Roberts & Mann 2003;Phillips et al. 2005) or for her unborn child (Siegel et al.
2001;Richter et al. 2002). Finally, several reports indicated that women did not want others to
notice them taking pills, as this would reveal their seropositive status to others (Roberts &
Mann 2000;Erlen et al. 2002;Garcia-Teague 2002;Sankar et al. 2002;Durante et al. 2003;Jones
et al. 2003;Powell-Cope et al. 2003;Phillips et al. 2005).
Although the negative effects of drug regimens are more prominent in the study results than
the positive effects, they are also less relevant to current practice. For example, the problem
of medication side-effects has been greatly reduced by the newer regimens. Moreover, better
understanding of the side-effects of these newer regimens has led to improved supportive or
pharmacologic assistance to offset them. Because more drug options exist, clinicians can avoid
drugs that tend to cause severe side-effects. Contemporary regimens are much simpler,
typically involve a smaller pill burden (i.e. number, size and taste), once- to twice-a-day dosing,
and often have no dietary requirements or restrictions, thereby making them easier to adhere
to as prescribed. They also make it easier to maintain privacy.
One way of dealing with these rapid changes in treatment regimens is to use time as a variable
to be studied. The history of treatment was actually the independent variable in Schrimshaw
et al.’s (2005) study, one of the 42 studies we reviewed. Indeed, this study serves as a model
for using history as one way to group studies in systematic reviews for analysis and
interpretation. Explicitly addressing antiretrovi-ral adherence in women in the pre-HAART
and HAART eras, they found that in comparison with women in the HAART era, women in
the pre-HAART era were more likely to report that they were not currently taking any
antiretroviral medication; were more likely to be on single drug monotherapies, as opposed to
dual therapies; held more negative views of toxicity of therapy as a whole; were more likely
to base their views on others’ experiences; were less likely to report benefits of therapy; were
more likely to hold strongly negative attitudes about the side-effects of therapy; and were more
likely to discontinue therapy as a way to manage side-effects. In comparison with women in
the pre-HAART era, women in the HAART era were more likely to be on triple drug
combination therapy, as opposed to dual drug therapy; held more balanced views of costs and
benefits of therapy; were less generally negative about therapy as a whole; held more negative
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views of specific drugs as opposed to all drugs; were less likely to be concerned about the
safety of medications; were more likely to be concerned about the daily hassles of taking the
medications; were more likely to see and report benefits of therapy; were more likely to be
optimistic about therapy; and were more likely to tolerate or try to manage side-effects (as
opposed to discontinuing therapy), or expect to be switched to another drug.
Following this model, the studies we reviewed can be grouped for analysis encompassing pre-
HAART (<1996), complex HAART (1996–2005) and simpler HAART (>2005) regimens.
This would permit analysis of how and what studies in each group contributed to the findings.
History of research on target disease or treatment
In addition to changes that must be accounted for in systematic reviews in the evolution of a
target disease and its treatment are changes in the research addressing them. Thorne et al.
(2002) emphasized the importance of assessing larger trends and patterns in the way clinical
problems are studied, including such key factors as changes in theoretical frameworks and
methodological fashions and fads. In the case of the antiretroviral adherence reports in our
study, key considerations included mapping the different ways that adherence and non-
adherence were conceptually and operationally defined and measured, and then linked to drug
regimens. We discerned from this work that at least 30 different definitions of adherence were
used. Over the years, antiretroviral adherance studies have shown varying alleglances to self-
report, pill counts, MEMS caps, direct observation and review of pharmaceutical records as
ways to capture adherance practices. In the studies we reviewed, adherance was measured using
standardized tools in 14 of the reports, author-developed questionnaires in 9 of the reports, pill
counts in four reports, pharmacy records in three reports, and MEMS (Medication Event
Monitoring System) caps, in two reports (some reports used multiple measures). Especially
relevant to time is that embedded in these definitions and measures are temporal definitions of
adherence. For example, adherence was variously operationalized as having taken drugs as
prescribed over the last day, 2 days, 3 days, 4 days, 6 days (out of a week), 1 week, 2 weeks,
1 month, 3 months, 6 months, or all the time; some of the studies did not specify what time
period they were measuring.
Yet another time-related trend is that virtually all of the studies we reviewed were cross-
sectional, as opposed to longitudinal, in design, thereby perpetuating the view of adherence as
a yes/no, static outcome, as opposed to a dynamic process that changes over time. Of the 42
reports, only four offered results at two or more time points. In addition, the reports of studies
are characterized by a lack of information on treatment experience (i.e. whether participants
were treatment-naïve or treatment-experienced) and on where in the disease and treatment life
cycle participants were at the time of data collection. Of the 42 reports, only five offered
information on treatment experience, which would be critical to frame the participants’
encounters with antiretroviral medications, especially now that treatment changes are generally
made with resistance testing after the first failed regimen. Twenty-eight studies offered
information on participants’ HIV disease severity, but offered no other information to link
disease severity and treatment experience.
Already well documented in the systematic review literature is the role methodological
differences play in multiplying the heterogeneity of studies in common domains of research
(Glasziou & Sanders 2002; Deeks et al. 2005). In the adherence studies we reviewed, the
temporal dimensions embedded in the very design of studies and in the conceptualization and
operationalization of the key dependent variable constitute a source of heterogeneity that have
to be accounted for in determining what findings are comparable enough to be combined.
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Time is a key element that must be managed throughout the trajectory of the systematic review
process to ensure clinically relevant research syntheses. Time considerations enter into the: (i)
formulation of research problem and question; (ii) setting of parameters for search and retrieval
of studies; (iii) determination of inclusion and exclusion criteria; (iv) appraisal of the clinical
relevance of findings; (v) selection of the findings that will be synthesized; and (vi)
interpretation of the results of that synthesis.
In addition to documenting the temporal boundaries for inclusion and when reports were
retrieved, reviewers should draw from their knowledge of the diagnosis or treatment under
review to interpret the significance of these temporal parameters. Reviewers must address how
they will treat reports where the dates of data collection are unavailable. They must also
differentiate between reports that are temporally irrelevant and therefore are candidates for
exclusion, and reports in which only certain findings are temporally irrelevant but others remain
relevant and therefore remain candidates for inclusion. We are in the process of answering
these questions as we begin selecting results for synthesis.
Authors of primary reports should always include the period of data collection and the timing
of data collection vis-à-vis the target events featured in the study (e.g. interviews were
conducted within 2 months of diagnosis). And publishers of systematic reviews should attempt
to reduce the time between submission of a completed review and its publication to preserve
its timeliness. With rapid advances in health care and proliferation of studies in which these
advances play a central role, systematic reviews become out-of-date virtually as soon as they
are completed.
In conclusion, time is a key factor in the systematic review process, an important covariate in
assessing the heterogeneity of studies, and a major determinant of the clinical relevance of
systematic reviews. Indeed, the viability of systematic reviews as a foundation for evidence-
based practice rests on adequate considerations of time.
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Table 1
Temporal profile of reports (n = 42)
Year(s) data collected References Department of Health and Human Services Guidelines
Do not know Misener & Sowell 1998
Do not know Fourney 1999
Do not know Richter et al. 2002
Do not know Douglass et al. 2003
Do not know Feigel 2003
Do not know Phillips et al. 2005
1993–1995 Mostashari et al. 1998 No guidelines in place
1993–1996 Laine et al. 2000 No guidelines in place
1993–1996 Patania 2003 No guidelines in place
1993–1997 Turner et al. 2000 1993–1996: No guidelines
1997: Dual NRTI backbone + 1 PI
1993–2000 Stone et al. 2001 1993–1996: No guidelines
1997: Dual NRTI backbone + 1 PI
1998: Dual NRTI backbone + 1 or 2 PIs (EFZ added in Dec. 1998)
1999: Dual NRTI backbone (6 combos) + 1 or 2 PIs, or EFZ
2000: Dual NRTI backbone (4 combos) + 1 or 2 PIs, or EFZ
1994–1995 Siegel & Gorey 1997 No guidelines in place
1994–1996; 2000–2003 Schrimshaw et al. 2005 1994–1996: No guidelines in place
2000: Dual NRTI backbone (4 combos) + 1 or 2 PIs, or EFZ
2001–2002: EFZ, PI, or boosted PI + dual NRTI backbone
2003: EFZ + 3TC + (AZT or TDF or d4T) OR LPV/r + 3TC + (AZT or d4T)
1996–1997 Schuman et al. 2001 1996: No guidelines
1997: Dual NRTI backbone + 1 PI
1996–1997 Siegel et al. 2001 1996: No guidelines
1997: Dual NRTI backbone + 1 PI
1997 Mann 2001 Dual NRTI backbone + 1 PI
1997 Roberts & Mann 2000 Dual NRTI backbone + 1 PI
1997 Roberts & Mann 2003 Dual NRTI backbone + 1 PI
1997–1998 Ickovics et al. 2002 1997: Dual NRTI backbone + 1 PI
1998: Dual NRTI backbone + 1 or 2 PIs (EFZ added in Dec. 1998)
1997–1999 Jones et al. 2003 1997: Dual NRTI backbone + 1 PI
1998: Dual NRTI backbone + 1 or 2 PIs (EFZ added in Dec. 1998)
1999: Dual NRTI backbone + 1 or 2 PIs, or EFZ
1997–2000 Sharpe et al. 2004 1997: Dual NRTI backbone + 1 PI
1998: Dual NRTI backbone + 1 or 2 PIs (EFZ added in Dec. 1998)
1999: Dual NRTI backbone (6 combos) + 1 or 2 PIs, or EFZ
2000: Dual NRTI backbone (4 combos) + 1 or 2 PIs, or EFZ
1998 Durante et al. 2003 Dual NRTI backbone + 1 or 2 PIs (EFZ added in Dec. 1998)
1998 Erlen et al. 2002 Dual NRTI backbone + 1 or 2 PIs (EFZ added in Dec. 1998)
1998–1999 Mellins et al. 2002 1998: Dual NRTI backbone + 1 or 2 PIs (EFZ added in Dec. 1998)
1999: Dual NRTI backbone + 1 or 2 PIs, or EFZ
1998–1999 Mellins et al. 2003 1998: Dual NRTI backbone + 1 or 2 PIs (EFZ added in Dec. 1998)
1999: Dual NRTI backbone + 1 or 2 PIs, or EFZ
1998–1999 Sowell et al. 2001a 1998: Dual NRTI backbone + 1 or 2 PIs (EFZ added in Dec. 1998)
1999: Dual NRTI backbone + 1 or 2 PIs, or EFZ
1998–1999 Sowell et al. 1999 1998: Dual NRTI backbone + 1 or 2 PIs (EFZ added in Dec. 1998)
1999: Dual NRTI backbone + 1 or 2 PIs, or EFZ
1998–1999 Sowell et al. 2001b 1998: Dual NRTI backbone + 1 or 2 PIs (EFZ added in Dec. 1998)
1999: Dual NRTI backbone + 1 or 2 PIs, or EFZ
1998–1999 Wilson et al. 2002 1998: Dual NRTI backbone + 1 or 2 PIs (EFZ added in Dec. 1998)
1999: Dual NRTI backbone + 1 or 2 PIs, or EFZ
1998–1999 Wilson et al. 2001 1998: Dual NRTI backbone + 1 or 2 PIs (EFZ added in Dec. 1998)
1999: Dual NRTI backbone + 1 or 2 PIs, or EFZ
1999 Howard et al. 2002 Dual NRTI backbone + 1 or 2 PIs, or EFZ
1999 Nguyen 2000 Dual NRTI backbone + 1 or 2 PIs, or EFZ
1999–2000 Kalichman et al. 2001 1999: Dual NRTI backbone (6 combos) + 1 or 2 PIs, or EFZ
2000: Dual NRTI backbone (4 combos) + 1 or 2 PIs, or EFZ
1999–2000 Murphy et al. 2002 1999: Dual NRTI backbone (6 combos) + 1 or 2 PIs, or EFZ
2000: Dual NRTI backbone (4 combos) + 1 or 2 PIs, or EFZ
1999–2000 Sankar et al. 2002 1999: Dual NRTI backbone (6 combos) + 1 or 2 PIs, or EFZ
2000: Dual NRTI backbone (4 combos) + 1 or 2 PIs, or EFZ
1999–2002 Hirokawa 2003 1999: Dual NRTI backbone (6 combos) + 1 or 2 PIs, or EFZ
2000: Dual NRTI backbone (4 combos) + 1 or 2 PIs, or EFZ
2001–2002: EFZ, PI, or boosted PI + dual NRTI backbone
2000 Powell-Cope et al. 2003 Dual NRTI backbone + 1 or 2 PIs, or EFZ
2000–2001 Abel & Painter 2003 2000: Dual NRTI backbone + 1 or 2 PIs, or EFZ
2001: EFZ, PI, or boosted PI + 2 NRTIs
2000–2001 Garcia-Teague 2002 2000: Dual NRTI backbone + 1 or 2 PIs, or EFZ
2001: EFZ, PI, or boosted PI + 2 NRTIs
2001 Gant & Welch 2004 EFZ, PI, or boosted PI + 2 NRTIs
2001 Wood et al. 2004 EFZ, PI, or boosted PI + dual NRTI backbone
2001–2003 Wyatt et al. 2004 2001–2002: EFZ, PI, or boosted PI + dual NRTI backbone
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2003: EFZ + 3TC + (AZT or TDF or d4T) OR LPV/r + 3TC + (AZT or d4T)
AZT, zidovudine; d4T, stavudine; EFZ, efavirz; LPV, lopinavir; NRTI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; r, ritonavir; 3TC,
lamivudine; TDF, tenofovir.
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